Kumar B Rajan1,2, Lisa L Barnes2, Robert S Wilson3, Jennifer Weuve4, Elizabeth A McAninch5, Denis A Evans5. 1. Department of Public Health Sciences, University of California at Davis, Davis, CA. 2. Alzheimer's Disease Center, University of California at Davis, Chicago, IL. 3. Rush Alzheimer's Disease Center, Chicago, IL. 4. Department of Epidemiology, Boston University School of Public Health, Boston, MA. 5. Department of Internal Medicine, Rush University Medical Center, Chicago, IL.
Abstract
OBJECTIVE: To examine the association of blood pressure (BP) with incident Alzheimer's disease (AD) dementia. METHODS: This work is based on a longitudinal, cohort study of 18 years, the Chicago Health and Aging Project (CHAP) performed in 2,137 participants (55% black) with systolic BP measured around 8.1 years before incident AD dementia. RESULTS: The association of BP with risk of AD dementia was U-shaped, with the lowest risks of AD dementia near the center of the systolic BP (SBP) and diastolic BP (DBP) distributions, and modestly elevated risk at lower BPs, and greater risk at higher BPs. The degree of U-shape and the range of lowest risk (threshold ranges) varied with antihypertensive medication use and presence of the APOE ε4 allele. The U-shape was most prominent for the subgroup not taking antihypertensive medications and having an APOE ε4 allele. At higher BPs, those having the APOE ε4 allele and not receiving antihypertensive medication were at greater risk of AD dementia than other groups: The risk of incident AD dementia increased by 100% (relative risk [RR] = 2.00; 95% confidence interval [CI] = 1.70, 2.31) for every 10 mm Hg increase in SBP above 140 mm Hg. For DBP, the risk of incident of AD dementia increased by 57% (RR = 1.57; 95% CI = 1.33, 1.86) for every 5 mm Hg increase in DBP above 76 mm Hg. INTERPRETATION: The BP risk of AD dementia association is U-shaped, with elevated risk at lower and higher BPs. People having the APOE ε4 allele and not receiving antihypertensive medication with higher BPs have notably elevated risk of AD dementia. Ann Neurol 2018;83:935-944.
OBJECTIVE: To examine the association of blood pressure (BP) with incident Alzheimer's disease (AD) dementia. METHODS: This work is based on a longitudinal, cohort study of 18 years, the Chicago Health and Aging Project (CHAP) performed in 2,137 participants (55% black) with systolic BP measured around 8.1 years before incident AD dementia. RESULTS: The association of BP with risk of AD dementia was U-shaped, with the lowest risks of AD dementia near the center of the systolic BP (SBP) and diastolic BP (DBP) distributions, and modestly elevated risk at lower BPs, and greater risk at higher BPs. The degree of U-shape and the range of lowest risk (threshold ranges) varied with antihypertensive medication use and presence of the APOE ε4 allele. The U-shape was most prominent for the subgroup not taking antihypertensive medications and having an APOE ε4 allele. At higher BPs, those having the APOE ε4 allele and not receiving antihypertensive medication were at greater risk of AD dementia than other groups: The risk of incident AD dementia increased by 100% (relative risk [RR] = 2.00; 95% confidence interval [CI] = 1.70, 2.31) for every 10 mm Hg increase in SBP above 140 mm Hg. For DBP, the risk of incident of AD dementia increased by 57% (RR = 1.57; 95% CI = 1.33, 1.86) for every 5 mm Hg increase in DBP above 76 mm Hg. INTERPRETATION: The BP risk of AD dementia association is U-shaped, with elevated risk at lower and higher BPs. People having the APOE ε4 allele and not receiving antihypertensive medication with higher BPs have notably elevated risk of AD dementia. Ann Neurol 2018;83:935-944.
Authors: Raj C Shah; Robert S Wilson; Julia L Bienias; Zoe Arvanitakis; Denis A Evans; David A Bennett Journal: Neuroepidemiology Date: 2005-10-25 Impact factor: 3.282
Authors: D Carmelli; C DeCarli; G E Swan; M Kelly-Hayes; P A Wolf; T Reed; J M Guralnik Journal: J Gerontol A Biol Sci Med Sci Date: 2000-02 Impact factor: 6.053
Authors: Denis A Evans; David A Bennett; Robert S Wilson; Julia L Bienias; Martha Clare Morris; Paul A Scherr; Liesi E Hebert; Neelum Aggarwal; Laurel A Beckett; Rajiv Joglekar; Elizabeth Berry-Kravis; Julie Schneider Journal: Arch Neurol Date: 2003-02
Authors: Félix Bermejo-Pareja; Julián Benito-León; Elan D Louis; Rocío Trincado; Eva Carro; Alberto Villarejo; Agustín Gómez de la Cámara Journal: J Alzheimers Dis Date: 2010 Impact factor: 4.472
Authors: Joan Lindsay; Danielle Laurin; René Verreault; Réjean Hébert; Barbara Helliwell; Gerry B Hill; Ian McDowell Journal: Am J Epidemiol Date: 2002-09-01 Impact factor: 4.897
Authors: Melina G H E den Brok; Esmé Eggink; Marieke P Hoevenaar-Blom; Willem A van Gool; Eric P Moll van Charante; Edo Richard; Jan Willem van Dalen Journal: Neurology Date: 2022-08-02 Impact factor: 11.800
Authors: Thanh Huyen T Vu; Todd Beck; David A Bennett; Julie A Schneider; Kathleen M Hayden; Aladdin H Shadyab; Kumar B Rajan; Martha Clare Morris; Marilyn C Cornelis Journal: Nutrients Date: 2022-07-03 Impact factor: 6.706
Authors: Jiandong Zhou; Sharen Lee; Wing Tak Wong; Khalid Bin Waleed; Keith Sai Kit Leung; Teddy Tai Loy Lee; Abraham Ka Chung Wai; Tong Liu; Carlin Chang; Bernard Man Yung Cheung; Qingpeng Zhang; Gary Tse Journal: J Am Med Inform Assoc Date: 2022-01-12 Impact factor: 7.942
Authors: Michael Ouk; Che-Yuan Wu; Jennifer S Rabin; Aaron Jackson; Jodi D Edwards; Joel Ramirez; Mario Masellis; Richard H Swartz; Nathan Herrmann; Krista L Lanctôt; Sandra E Black; Walter Swardfager Journal: Alzheimers Res Ther Date: 2021-02-11 Impact factor: 6.982